Back to top

Top Ranked Income Stocks to Buy for February 26th

Read MoreHide Full Article

Here are three stocks with buy rank and strong income characteristics for investors to consider today, February 26th:

Rio Tinto plc (RIO - Free Report) : This explorer, developer and processor of minerals and metals has witnessed the Zacks Consensus Estimate for its current year earnings increasing 33.3% over the last 60 days.

Rio Tinto PLC Price and Consensus

This Zacks Rank #1 (Strong Buy) company has a dividend yield of 4.31%, compared with the industry average of 0.00%. Its five-year average dividend yield is 4.74%.

Rio Tinto PLC Dividend Yield (TTM)

Omnicom Group Inc. (OMC - Free Report) : This marketing, advertising and communications services provider has witnessed the Zacks Consensus Estimate for its current year earnings increasing 3.2% over the last 60 days.

Omnicom Group Inc. Price and Consensus

This Zacks Rank #2 (Buy) company has a dividend yield of 3.17%, compared with the industry average of 0.00%. Its five-year average dividend yield is 2.79%.

Omnicom Group Inc. Dividend Yield (TTM)

GlaxoSmithKline plc (GSK - Free Report) : This vaccines and over-the-counter medicines manufacturer has witnessed the Zacks Consensus Estimate for its current year earnings increasing 3.2% over the last 60 days.

GlaxoSmithKline plc Price and Consensus

This Zacks Rank #2 (Buy) company has a dividend yield of 5.82%, compared with the industry average of 2.77%. Its five-year average dividend yield is 5.28%.

GlaxoSmithKline plc Dividend Yield (TTM)

See the full list of top ranked stocks here.

Find more top income stocks with some of our great premium screens.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Rio Tinto PLC (RIO) - free report >>

Omnicom Group Inc. (OMC) - free report >>

GlaxoSmithKline plc (GSK) - free report >>